119 related articles for article (PubMed ID: 27010394)
61. Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Armstrong P; Woody MM; Reichenberg JS; Gavino AC
Cutis; 2018 Sep; 102(3):E12-E14. PubMed ID: 30372726
[TBL] [Abstract][Full Text] [Related]
62. [Possibility of Prolonging Treatment by Preventing Paclitaxel-Induced Peripheral Neuropathy Using Compression Therapy].
Tsuyuki S; Hamada-Nishimoto M; Kang Y; Katayama T
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1241-1245. PubMed ID: 36412028
[TBL] [Abstract][Full Text] [Related]
63. [A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy].
Takano J; Matsuhashi N; Takahashi T; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Yoshida K
Gan To Kagaku Ryoho; 2018 Feb; 45(2):318-320. PubMed ID: 29483433
[TBL] [Abstract][Full Text] [Related]
64. [Skin Ulcer Caused by Bevacizumab-A Case Report].
Mori Y; Ishikawa A; Urano N; Higuchi I; Gofuku J; Hasuike Y
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2237-2239. PubMed ID: 32156890
[TBL] [Abstract][Full Text] [Related]
65. Same Data; Different Interpretations.
Gyawali B; Prasad V
J Clin Oncol; 2016 Nov; 34(31):3729-3732. PubMed ID: 27573659
[No Abstract] [Full Text] [Related]
66. Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project.
Ezzalfani M; Porcher R; Savignoni A; Delaloge S; Filleron T; Robain M; Pérol D;
PLoS One; 2021; 16(9):e0255017. PubMed ID: 34525119
[TBL] [Abstract][Full Text] [Related]
67. Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer.
Hamada-Nishimoto M; Kang Y; Shiraki E; Tsuyuki S
Int Cancer Conf J; 2021 Oct; 10(4):329-333. PubMed ID: 34567947
[TBL] [Abstract][Full Text] [Related]
68. A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Quan R; Huang J; Chen N; Fang W; Hu Z; Zhan J; Zhou T; Zhang L; Zhang H
Tumour Biol; 2016 Aug; 37(8):11479-84. PubMed ID: 27012553
[TBL] [Abstract][Full Text] [Related]
69. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
[TBL] [Abstract][Full Text] [Related]
70. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
71. Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.
Kordbacheh T; Law WY; Smith IE
Breast; 2016 Apr; 26():54-8. PubMed ID: 27017242
[TBL] [Abstract][Full Text] [Related]
72. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
[TBL] [Abstract][Full Text] [Related]
73. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
Feng YR; Zhu Y; Liu LY; Wang WH; Wang SL; Song YW; Wang X; Tang Y; Liu YP; Ren H; Fang H; Zhang SP; Liu XF; Yu ZH; Li YX; Jin J
Oncotarget; 2016 May; 7(18):25576-84. PubMed ID: 27014909
[TBL] [Abstract][Full Text] [Related]
74. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
[TBL] [Abstract][Full Text] [Related]
75. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Takashima T; Tokunaga S; Tei S; Nishimura S; Kawajiri H; Kashiwagi S; Yamagata S; Noda S; Nishimori T; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K
Springerplus; 2016; 5():164. PubMed ID: 27026861
[TBL] [Abstract][Full Text] [Related]
76. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
77. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
[TBL] [Abstract][Full Text] [Related]
78. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS
J Clin Oncol; 2016 Aug; 34(24):2858-65. PubMed ID: 27022118
[TBL] [Abstract][Full Text] [Related]
79. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
80. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
